In FAMMM patients, there is an estimated risk to develop pancreatic cancer 13–22 times higher than the risk in the average population, and the risk increases to more of 40‐fold in CDKN2A‐mutant FAMMM patients (Lynch et al. 2008; de Snoo et al. 2008). This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.